AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 194.81B +11.1% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.95 |
| Forward PE | 15.48 |
| Dividend | 2.39 (1.89%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 97,510 |
| Open | 12,624 |
| Previous Close | 12,560 |
| Day's Range | 12,598 - 12,684 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 15,804.21 (+25.25%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,804p, which is an increase of 25.25% from the latest price.
News
Astrazeneca (AZN) Ascends But Remains Behind Market: Some Facts to Note
In the latest trading session, Astrazeneca (AZN) closed at $168.1, marking a +1.22% move from the previous day.
FDA Grants Priority Review To AstraZeneca's Efzimfotase Alfa In Hypophosphatasia
(RTTNews) - Alexion, AstraZeneca Plc's (AZN) rare-disease unit, announced that the U.S. Food and Drug Administration(FDA) accepted and has granted priority review to the Biologics License Application(...
AstraZeneca's Enhertu, Klygefa Get Positive CHMP Opinions In EU
(RTTNews) - AstraZeneca (AZN), a biopharmaceutical company, said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Enhertu for an additi...
AstraZeneca: CHMP Recommends Enhertu For Approval In The EU
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo's (4568.T) Enhertu has been recommended for approval in the European Union by CHMP as a monotherapy for the adjuvant treatment o...
AZN Looks 8.8% Undervalued on GF Value™
AZN Looks 8.8% Undervalued on GF Value™
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
AZN Looks 8.9% Undervalued on GF Value™ After EU Nod for Klygefa
AZN Looks 8.9% Undervalued on GF Value™ After EU Nod for Klygefa
AZN Looks 8.9% Undervalued on GF Value™ Amid Strong Dividend Profile
AZN Looks 8.9% Undervalued on GF Value™ Amid Strong Dividend Profile
AZN Looks 8.9% Undervalued on GF Value™ with Solid Dividend Sustainability
AZN Looks 8.9% Undervalued on GF Value™ with Solid Dividend Sustainability
AstraZeneca, Alexion’s Klygefa recommended for approval in EU
Alexion, AstraZeneca (AZN) Rare Disease’s Klygefa has been recommended for approval in the European Union, EU, as an add-on to standard therapy for the treatment of generalised myasthenia gravis in…
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) Enhertu has been recommended for approval in the European Union, EU, as a monotherapy for the adjuvant treatment of adult patients with resected HER2-pos...
AstraZeneca’s Enhertu recommended for approval in the EU by CHMP
Enhertu has been recommended for approval in the European Union as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive…
Daiichi Sankyo: Enhertu Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca's Enh...
AZN Looks 8.9% Undervalued on GF Value™ Amid Dividend Sustainability
AZN Looks 8.9% Undervalued on GF Value™ Amid Dividend Sustainability
AstraZeneca CEO Buys Shares at £121.02 (AZN)
AstraZeneca CEO Buys Shares at £121.02 (AZN)
AstraZeneca’s BLA for efzimfotase alfa accepted, granted Priority Review by FDA
Alexion, AstraZeneca’s (AZN) Rare Disease’s Biologics License Application, BLA, for efzimfotase alfa has been accepted and granted Priority Review by the US Food and Drug Administration, FDA, for the ...
AstraZeneca Gains as Enhertu Clears England's Value Gate
AstraZeneca Gains as Enhertu Clears England's Value Gate
AstraZeneca's Enhertu Gets NICE Recommendation For HER2 Low Metastatic Breast Cancer
(RTTNews) - AstraZeneca (AZN) and Daiichi Sankyo (4568.T) announced that Enhertu (trastuzumab deruxtecan) has received a positive recommendation from the National Institute for Health and Care Excelle...
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's state-run healthcare system, expanding access to a drug that has been ava...
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian h...
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Under Scrutiny
Enhertu Approved by NICE for NHS, Impact on AstraZeneca (AZN) Under Scrutiny
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
AstraZeneca Shares Rise as J.P. Morgan Stays Overweight
AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg
Berenberg analyst Luisa Hector lowered the firm’s price target on AstraZeneca (AZN) to 150 GBp from 160 GBp and keeps a Buy rating on the shares.
AstraZeneca upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank upgraded AstraZeneca (AZN) to Hold from Sell with a price target of 11,700 GBp, up from 11,500 GBp. The firm cites valuation for the upgrade with the shares…
Why the Market Dipped But Astrazeneca (AZN) Gained Today
In the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.